Baird analyst Brian Skorney is incrementally positive on Proteostasis Therapeutics' (NASDAQ: PTI) FDA breakthrough designation for PTI-428.Skorney said the FDA ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE